Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:GBT 16 August 2025 - 18 August 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········

Stock Market Today

  • RTX Shares See 52% Gain in Year - Is It Overvalued at $200?
    March 20, 2026, 1:45 AM EDT. RTX's share price rose 51.8% over the past year but dropped 1.4% last month, trading around $200.73. A Discounted Cash Flow (DCF) analysis values RTX at $183.11, suggesting the stock is about 9.6% overvalued based on projected free cash flows. Despite promising aerospace and defense sector positioning, valuation signals are mixed, with a 3 out of 6 score indicating both undervaluation and fair pricing factors. Investors should watch RTX closely for market shifts and updates to fundamentals that could affect its value.
Go toTop